At Sandoz, we discover new ways to improve and extend people’s lives. We pioneer novel approaches to help people around the world access high-quality medicine. In 2015, our products reached an estimated 500 million patients and our aspiration is to reach one billion.
In addition to being a global leader in generic pharmaceuticals, biosimilars and a pioneer in the emerging field of prescription digital therapeutics, Sandoz holds leading global positions in areas ranging from generic cardiovascular, central nervous system (CNS), pain, ophthalmology, oncology and respiratory.
Our broad portfolio is backed by a range of state-of-the-art technologies, formulations and devices, including prolonged-release and multiple-unit tablets, creams and gels, orodispersible films, transdermal patches, lyophilized products, implants and inhalers.